Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2025 09:35 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Publishes Early Results Showing Telomere Elongation in First Gene Therapy Trial for Telomere Biology Disorders

Data published in NEJM Evidence detail the first clinical test of ZSCAN4 for telomere elongation. Treatment with EXG-34217 resulted in in vivo telomere elongation in a subpopulation of lymphocytes to...
February 20, 2025 16:05 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of Telomere Biology Disorders

BALTIMORE, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on treating rare diseases, today announced that the U.S. Food and Drug...
February 13, 2025 08:30 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EXG-34217 for Treatment of Telomere Biology Disorders

BALTIMORE, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on treating rare diseases, today announced that the U.S. Food and Drug...
September 25, 2024 08:00 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders

BALTIMORE, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its...
March 04, 2024 08:00 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Bobcat mRNATM technology is a novel linear mRNA platform able to encode large proteins Data showed restoration of muscular function in DMD mouse model BALTIMORE, March 04, 2024 (GLOBE NEWSWIRE) --...
October 16, 2023 08:00 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2

No safety concerns were observed with EXG-5003 administration The data suggest a priming effect by EXG-5003 on the long-term cellular immunity of approved SARS-CoV-2 mRNA vaccines The Company is...
January 26, 2023 08:00 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration

BALTIMORE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its...
January 04, 2023 08:00 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference

BALTIMORE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its...
December 21, 2022 08:00 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors

BALTIMORE, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its...
December 12, 2022 11:30 ET | Source: Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting

Treatment with EXG-34217 increased the telomere length of CD34+ cells by 1.24-fold ex vivoTelomere flow-FISH study suggests the potential emergence of a cell population with longer telomeres in vivoNo...